BioVie Statistics
Share Statistics
BioVie has 17.77M shares outstanding. The number of shares has increased by -79.62% in one year.
| Shares Outstanding | 17.77M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -87.42% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 15.36M |
| Failed to Deliver (FTD) Shares | 34.89K |
| FTD / Avg. Volume | 0.58% |
Short Selling Information
The latest short interest is 1.92M, so 10.81% of the outstanding shares have been sold short.
| Short Interest | 1.92M |
| Short % of Shares Out | 10.81% |
| Short % of Float | 12.51% |
| Short Ratio (days to cover) | 0.15 |
Valuation Ratios
The PE ratio is -0.59 and the forward PE ratio is -0.76.
| PE Ratio | -0.59 |
| Forward PE | -0.76 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.22 |
| P/FCF Ratio | -0.67 |
| PEG Ratio | n/a |
Enterprise Valuation
BioVie Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.57, with a Debt / Equity ratio of 0.37.
| Current Ratio | 2.57 |
| Quick Ratio | 2.57 |
| Debt / Equity | 0.37 |
| Total Debt / Capitalization | 26.88 |
| Cash Flow / Debt | -4.9 |
| Interest Coverage | -11.12 |
Financial Efficiency
Return on equity (ROE) is -2.07% and return on capital (ROIC) is -148.86%.
| Return on Equity (ROE) | -2.07% |
| Return on Assets (ROA) | -1.27% |
| Return on Capital (ROIC) | -148.86% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.29M |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -81.79% in the last 52 weeks. The beta is 0.9, so BioVie 's price volatility has been higher than the market average.
| Beta | 0.9 |
| 52-Week Price Change | -81.79% |
| 50-Day Moving Average | 2.54 |
| 200-Day Moving Average | 3.92 |
| Relative Strength Index (RSI) | 45.19 |
| Average Volume (20 Days) | 6.03M |
Income Statement
In the last 12 months, BioVie had revenue of $0 and earned -$32.12M in profits. Earnings per share was $-7.3.
| Revenue | 0 |
| Gross Profit | -229.38K |
| Operating Income | -32.18M |
| Net Income | -32.12M |
| EBITDA | -31.95M |
| EBIT | - |
| Earnings Per Share (EPS) | -7.3 |
Balance Sheet
The company has $23.84M in cash and $6.11M in debt, giving a net cash position of $17.73M.
| Cash & Cash Equivalents | 23.84M |
| Total Debt | 6.11M |
| Net Cash | 17.73M |
| Retained Earnings | -334.23M |
| Total Assets | 21.24M |
| Working Capital | 13.31M |
Cash Flow
In the last 12 months, operating cash flow was -$27.95M and capital expenditures $0, giving a free cash flow of -$27.95M.
| Operating Cash Flow | -27.95M |
| Capital Expenditures | 0 |
| Free Cash Flow | -27.95M |
| FCF Per Share | -6.18 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
BIVI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -276.52% |
| FCF Yield | -59.57% |
Analyst Forecast
The average price target for BIVI is $30, which is 1036.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $30 |
| Price Target Difference | 1036.4% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Aug 6, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Aug 6, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -21.36 |
| Piotroski F-Score | 3 |